Esperion Therapeutics Inc (ESPR)

[north40000]

I posed the following rhetorical question last Sunday, the 19th, before becoming aware of the results reached by ESPR on Monday, the 20th. I have not reached any contrary answer to the question as yet.

"Should I be interested in any of the companies that have reacted negatively to the results posted by AMGN for Repatha, apart from other entities/items present in respective pipelines"?

Currently I am not interested. My own monthly cost for AMRN's Vascepa is much lower---$37/month co-pay for my off-label prescription---than the prognosticated cost of Repatha[$14,500/year] or ESPR's treatment drug[estimated $3000/year]. The benefits of Vascepa for me seem to = or exceed anything Repatha or competition, including ESPR, would offer in CVD arena. My 2016 lipid panel data is posted on the Amarin IHub board. The data is from blood samples taken at my last annual physical in March 2016, and will be up-dated in March 2017. I will be 80 years old in April 2017.

The EPA/AA ratio is becoming widely recognized as a marker for inflammation in the CV system---my value of 1.3 is particularly good, probably better than the vast majority of the U.S. population. My doctor termed my lipid profile as "excellent," and my cardiovascular risk as "optimally suppressed."

Below are the current lipid panel marker values for me. I have been prescribed Vascepa[an oral capsule containing 96%(1 gram) of an omega-3 fatty acid known as EPA, or icosapent ethyl], Off-label, since 4/1/2013.

Generic Zocor = 40 mg dose > 20 years. T1 diabetic since 1957.
HbA1c = 6.5; FBG= 111 mg/dL

Total cholesterol = 144 mg/dL
LDL-C = 70 mg/dL
TGCs = 63. "
HDL = 61. "
VLDL = 13. "

C-reactive
protein = 2.2 mg/L

APO B = 60 mg/dL;
Lp-PLA2 = 216, termed very slightly elevated;
EPA/AA Ratio = 1.3;
Omega-6/Omega-3 ratio = 1.8;
EPA = 7.0% ;
AA = 5.3%;
DHA = 2.1%;

Omega-3(EPA + DHA) Index = 9.1%, optimal > 3.2%


Vascepa also obliterated the DES I once had within days of 1st dose in April 2013. DES remains gone today. Vascepa has no known side effects. AGN and SHPG should be concerned also to the extent reliance is had for their respective DES treatments to be accretive to revenue and earnings.
Is DES one of the secondary or tertiary indications/utilities for which Amarin may file with the FDA per its 1st Amendment settlement with FDA last year? Further background of Amarin and Vascepa may be found here:

http://www.fdalawblog.net/Amarin%20%2800193135%29.pdf
http://tinyurl.com/zyduacf
http://tinyurl.com/jabzuvw
http://tinyurl.com/jumnoej
http://tinyurl.com/zoxx9x4
http://tinyurl.com/zb8rnqu
http://tinyurl.com/jnx6w6p